Explore TIGIT

Targeting TIGIT: A novel immune checkpoint

TIGIT (T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains) is a novel negative immune checkpoint, expressed on T cells and NK cells.^1,2

TIGIT is a coinhibitory receptor that binds to PVR on APCs and tumor cells in various solid and hematologic tumors.^1-3 TIGIT dampens the immune response by competing with its costimulatory counterpart, CD226, for binding to PVR.^1,2 Preventing PVR-TIGIT interaction may restore anti-tumor immunity, thereby complementing PD-L1 inhibition, as shown in preclinical models.¹ TIGIT was identified at Genentech.^2,4

Targeting PVR-TIGIT interaction may be one approach³

Preclinical studies suggest that targeting both TIGIT and PD-L1 may synergistically enhance immune-mediated tumor rejection.^1,5,6

Targeting TIGIT may enhance T_eff  function.¹

Targeting TIGIT may activate NK cells.⁵

Targeting TIGIT may counter T reg-mediated immune suppression.⁶

APC=antigen-presenting cell; IgG1=immunoglobulin G1; NK=natural killer; PD-1=programmed cell death protein 1; PD-L1=programmed cell-death ligand 1; PVR=poliovirus receptor; T_eff=effector T cell; T_reg=regulatory T cell; TIGIT=T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains.